{"id":1271,"date":"2014-07-21T03:00:35","date_gmt":"2014-07-21T07:00:35","guid":{"rendered":"https:\/\/issels.com\/blog\/?p=1271"},"modified":"2015-02-02T20:00:33","modified_gmt":"2015-02-03T01:00:33","slug":"immunotherapy-in-the-news-2","status":"publish","type":"post","link":"https:\/\/issels.com\/blog\/2014\/07\/21\/immunotherapy-in-the-news-2\/","title":{"rendered":"Immunotherapy In The News"},"content":{"rendered":"
\"In
In The News<\/figcaption><\/figure>\n

Immunotherapy for cancer \u2013 the use of a patient\u2019s own antibodies to create cancer-blocking properties \u2013 has been called everything from the disease\u2019s potential \u201coff-switch<\/a>\u201d to the \u201cbeginning of the end of chemotherapy.\u201d<\/p>\n

In recent immunotherapy news, Israel-based Compugen announced in July what it calls a milestone<\/a> in cancer immunotherapy collaboration. Working with Bayer HealthCare, Compugen aims to develop and commercialize \u201ctherapeutic antibodies against two checkpoint protein candidates discovered by Compugen,\u201d as the company\u2019s website puts it.<\/p>\n

\u201cWe are very pleased by the achievement of this initial drug development milestone for one of the two programs in our collaboration with Bayer,\u201d said Compugen President and CEO Dr. Anat Cohen Dayag. \u201cAfter investing more than a decade of extensive multidisciplinary research in establishing our broadly applicable predictive discovery infrastructure, we selected the area of checkpoint-based cancer immunotherapy as our first focused discovery effort.\u00a0 Therefore, it is extremely satisfying to see our growing competitive position, in terms of both advancement of our therapeutic programs in immuno-oncology and continuing discoveries of novel targets in this exciting area, which is increasingly being viewed as a potential major breakthrough in cancer treatment.\u201d<\/p>\n

More immunotherapy news<\/strong>
\nOn July 13, Business Standard<\/a> reported that an immunotherapy treatment had been developed to treat cancer in dogs. \u201cScientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna discovered that a receptor frequently found on human tumour cells (epidermal growth factor receptor or EGFR) is nearly 100 per cent identical with the EGF receptor in dogs,\u201d as the Press Trust noted. Scientists noted that \u201cdue to the high similarity of the receptor in humans and dogs, this type of therapy should work well in dogs too.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Immunotherapy for cancer \u2013 the use of a patient\u2019s own antibodies to create cancer-blocking properties \u2013 has been called everything from the disease\u2019s potential \u201coff-switch\u201d to the \u201cbeginning of the end of chemotherapy.\u201d In recent immunotherapy news, Israel-based Compugen announced in July what it calls a milestone in cancer immunotherapy collaboration. Working with Bayer HealthCare, … Continue reading Immunotherapy In The News<\/span> →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[216,2],"tags":[282,212],"class_list":["post-1271","post","type-post","status-publish","format-standard","hentry","category-immunotherapy","category-news","tag-cancer-news","tag-cancer-research"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/1271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/comments?post=1271"}],"version-history":[{"count":1,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/1271\/revisions"}],"predecessor-version":[{"id":1273,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/1271\/revisions\/1273"}],"wp:attachment":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/media?parent=1271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/categories?post=1271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/tags?post=1271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}